CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. (CTMX): 8 pipeline candidates · ~39 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
39.1 months
D/E 0.12
Lead: Phase 2
8 candidates
N/A
0 buys · 4 sells (180d)
A transparent, data-derived signal for CytomX Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$637.9M
Cash
$28.8M
Quarterly Burn
$25.5M
Runway
39.1 mo
Revenue
$10.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| BMS-986249 | Phase 2 |
| BMS-986288 | Phase 2 |
| CX-2029 | Phase 2 |
| CX-2051 | Phase 1 |
| CX-801 | Phase 1 |
| CX-904 | Phase 1 |
| cx-908 | Preclinical |
| varsetatug masetecan | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
178
Total value held
$871.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 31,955,637 | $150.2M |
| perceptive advisors llc | 20,197,648 | $94.9M |
| vanguard capital management llc | 17,466,236 | $82.1M |
| bank of america corp /de/ | 10,202,785 | $48.0M |
| citadel advisors llc | 5,899,193 | $27.7M |
| state street corp | 5,663,408 | $26.6M |
| blackrock, inc. | 5,228,280 | $24.6M |
| baker bros. advisors lp | 4,975,826 | $23.4M |
| elmind capital, lp | 4,550,000 | $21.4M |
| nextech invest, ltd. | 4,449,932 | $20.9M |
Showing top 10 of 178 institutional holders of CytomX Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CytomX Therapeutics, Inc.'s pipeline?
CytomX Therapeutics, Inc. (CTMX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CytomX Therapeutics, Inc.'s lead drug candidate?
CytomX Therapeutics, Inc.'s most advanced tracked candidate is BMS-986249 (Phase 2) for Advanced solid tumors (investigated alone and in combination with nivolumab).
What is CytomX Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CytomX Therapeutics, Inc. has approximately 39.1 months of cash runway.
What is CytomX Therapeutics, Inc.'s market capitalization?
CytomX Therapeutics, Inc.'s market capitalization is approximately $637.9M.
Who is the CEO of CytomX Therapeutics, Inc.?
Dr. Sean A. McCarthy DPHIL is the chief executive officer of CytomX Therapeutics, Inc. (CTMX).
Get the full picture on CytomX Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.